NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Biomarker Signature for IV Sapu003 Sensitivity
TL;DR
Oncotelic Therapeutics' biomarker discovery offers a strategic edge by enabling targeted Sapu003 treatment for mTORC2-dominant tumors, potentially improving clinical outcomes and market positioning.
Sapu Nano's biomarker framework analyzes over 9,000 tumor samples to identify High-RICTOR/Low-RPTOR signatures, predicting sensitivity to intravenous Sapu003 for mTORC2-dominant cancers across 20 types.
This advancement could enhance cancer treatment precision, offering hope for patients with resistant tumors and potentially improving survival rates and quality of life.
Oncotelic's intravenous Sapu003 formulation overcomes oral everolimus limitations with higher tissue penetration and reduced GI accumulation, targeting multiple cancers including breast and lung.
Found this article helpful?
Share it with your network and spread the knowledge!
Oncotelic Therapeutics reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company's intravenous Deciparticle™ formulation of everolimus.
Sapu003 is an intravenous Deciparticle™ formulation of everolimus that overcomes limitations of oral everolimus through higher tissue penetration, reduced GI accumulation, and preserved metabolic specificity.
mTORC2-dominant tumors including HR+/HER2- breast, lung adenocarcinoma, gastric, renal, ovarian, AML and T-cell malignancies exhibit heightened mTOR dependency and predicted sensitivity to Sapu003.
The biomarker framework will be presented at the 2025 San Antonio Breast Cancer Symposium.
This represents the first prospective selection strategy for IV everolimus and is based on analysis of more than 9,000 tumor samples across 20 cancer types, potentially enabling more targeted and effective cancer treatment.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products to address high-unmet-need cancers and rare pediatric indications.
Sapu Nano is a joint venture that is 45% owned by Oncotelic Therapeutics, and it has identified the biomarker signature predicting sensitivity to Sapu003.
The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
InvestorWire is a specialized communications platform that provides wire-grade press release syndication and is part of the IBN (InvestorBrandNetwork) portfolio, which distributed this content about Oncotelic Therapeutics.
Curated from InvestorBrandNetwork (IBN)
